- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04115020
Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis
Study Overview
Status
Intervention / Treatment
Detailed Description
Chronic pain affects over 100 million Americans, and arthritis is the most common cause. Existing treatments for chronic arthritic pain are only mildly effective, and risks of medications used to treat pain are numerous and continue to be discovered.
Naltrexone is an opioid antagonist that is FDA approved in an oral daily dose of 50 mg to prevent recidivism in alcoholics. At much lower doses of 4 - 4.5 mg daily, however, it has been shown in small, blinded, randomized trials to improve pain in fibromyalgia, gastrointestinal symptoms in Crohn's disease, and quality of life in multiple sclerosis. The only other published data are case reports in complex regional pain syndrome, low back pain, and scleroderma. However, advocacy of low-dose naltrexone (LDN) by internet-based MDs and patients is high, and since LDN can be prescribed off-label, its use greatly exceeds what is justified by evidence. The drug can be prescribed only via compounding pharmacies, so its use costs a patient ~$40/month.
Among the many unproven treatments that are widely used, LDN is of particular interest because results of surveys of patients are particularly impressive, because it is quite safe, and because its benefit is plausible pharmacologically. There is evidence both for modulation of central pain-processing pathways and for down-regulation of inflammatory pathways in microglia. Considering the diversity of conditions proposed to benefit from LDN and the unequivocal need for better approaches to pain relief in chronic conditions, high-quality clinical trials are needed in both inflammatory and non-inflammatory conditions. This small but placebo-controlled study, powered to detect an effect size as small as that seen with NSAIDs or the most beneficial non-pharmacologic approaches, is being conducted as a prerequisite for considering a pivotal trial.
The proposed study is a randomized, double-blinded, cross-over, placebo-controlled trial in adults with osteoarthritis or inflammatory arthritis and persistent pain. Thirty patients will be enrolled for 16 weeks, during which they will receive LDN for 8 weeks and placebo for 8 weeks. Widely accepted patient-reported outcome measures will be used. The co-primary endpoints are reduction in pain severity or pain's interference with function during 8 weeks of LDN compared to 8 weeks placebo, using the Brief Pain Inventory. Other patient-reported data will be used both as secondary outcomes and as covariates in analyzing determinants of response to treatment. Data from this study will be analyzed in combination with data from a study conducted with 30 patients at the VA, to be completed in 2019. A total of 60 patients in the two studies is sufficient to detect benefit similar to what is seen with NSAIDs.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- One or more of the following chronic conditions: osteoarthritis, rheumatoid arthritis, or non-axial spondyloarthritis
- Average daily pain interference with function (average of the 7 parts of question 9 on the Brief Pain Inventory) rated at least 4 on a scale of 0-10, and no higher than 9
- No change in medication in the past 8 weeks made with the expectation of improving pain
- No plan to start another medication or a non-pharmacologic treatment regimen likely to affect pain during the next 16 weeks
- Age at least 18
- Capable of informed consent, and willingness to comply with study procedures, including receipt of weekly phone calls from the study coordinator
Exclusion Criteria:
- Use of opioids including tramadol, in the past 7 days
- Pregnant, breast feeding, or unwilling to engage in contraceptive practices if sexually active and capable of conceiving
- Schizophrenia, bipolar disorder, or poorly controlled depression or anxiety
- Previous use of low-dose naltrexone for more than 8 weeks or in the past 2 weeks
- Back pain described by the patient as greater in severity than arthritic pain in all peripheral locations
- Significant kidney disease, defined as glomerular filtration rate < 30 ml/min
- Liver cirrhosis. There is no specific screening procedure to exclude cirrhosis.
- Peripheral neuropathy described by the patient as greater in severity than arthritic pain. There is no specific screening procedure.
- Plan to have surgery during the next 16 weeks
- Other qualitative circumstances that the investigator feels would make the patient a poor candidate for this clinical trial, such as an unstable social situation or unreliable transportation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Naltrexone first then placebo
Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
|
Naltrexone 4.5 mg oral suspension
Placebo oral suspension
|
Experimental: Placebo first then naltrexone
Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
|
Naltrexone 4.5 mg oral suspension
Placebo oral suspension
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brief Pain Inventory - Pain Interference
Time Frame: 16 weeks
|
Average of 7 questions on how much pain has interfered with general function, walking ability, mood, normal work, relations with other people, sleep, and enjoyment of life
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brief Pain Inventory - Pain Severity
Time Frame: 16 weeks
|
Average severity of pain in the past 7 days (0-10)
|
16 weeks
|
painDETECT
Time Frame: 16 weeks
|
Measure of neuropathic pain (0-38)
|
16 weeks
|
Brief Fatigue Inventory
Time Frame: 16 weeks
|
Questionnaire, severity of fatigue and fatigue's interference with activity (0-10 scales).
|
16 weeks
|
PROMIS-29
Time Frame: 16 weeks
|
Questionnaire, survey of health-related quality of life across 8 domains.
|
16 weeks
|
Beck Depression Inventory-II
Time Frame: 16 weeks
|
Questionnaire measuring severity of depression.
Used primarily during screening to exclude enrollment of patients with severe depression, but also as a safety outcome measure during the study.
|
16 weeks
|
Clinical Global Impression of Severity (CGI-S)
Time Frame: 16 weeks
|
7-point scale of patients' self-reporting of severity during the study.
|
16 weeks
|
Clinical Global Impression of Improvement (CGI-I)
Time Frame: 16 weeks
|
7-point scale of patients' self-reporting of improvement or worsening during the study
|
16 weeks
|
Pressure-pain threshold testing
Time Frame: 16 weeks
|
Measurement of minimum pressure needed to cause detectable pain at each knee
|
16 weeks
|
DAS-28
Time Frame: 16 weeks
|
Assessment of disease activity in rheumatoid arthritis (only for patients with rheumatoid arthritis)
|
16 weeks
|
BASDAI
Time Frame: 16 weeks
|
Assessment of disease activity by MD in spondyloarthritis (only for patients with spondyloarthritis)
|
16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paul Monach, MD, PhD, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Autoimmune Diseases
- Pain
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Skin Diseases, Papulosquamous
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Spondylarthritis
- Spondylitis
- Psoriasis
- Arthritis
- Arthritis, Rheumatoid
- Osteoarthritis
- Chronic Pain
- Arthritis, Psoriatic
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Narcotic Antagonists
- Alcohol Deterrents
- Naltrexone
Other Study ID Numbers
- 2019P001799
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Richard Burt, MDTerminated
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
-
National Eye Institute (NEI)CompletedUveitis | Arthritis, Juvenile RheumatoidUnited States
-
AmgenTerminated
Clinical Trials on Naltrexone
-
San Diego State UniversityRecruitingPlacebo | NaltrexoneUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem DrinkingUnited States
-
Alkermes, Inc.Terminated
-
Alkermes, Inc.Completed
-
Alkermes, Inc.Completed
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...CompletedOpioid-Related Disorders | Heroin DependenceUnited States, Russian Federation
-
Centre for Addiction and Mental HealthUnknown
-
State University of New York - Upstate Medical...CephalonCompletedAlcohol Dependence | Schizophrenia | Schizoaffective Disorders | Bipolar DisordersUnited States
-
Medical University of LublinRecruitingQuality of Life | Vulvodynia | NaltrexonePoland
-
University of Colorado, DenverWithdrawnAlcohol Use Disorder